Atherosclerosis: Cell biology and lipoproteins

Current Opinion in Lipidology

Volumn 20, Issue 3, 2009, Pages 260-261

  Daugherty, Alan ^a   Lu, Hong ^a   Rateri, Debra L ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN E; CERAMIDE; DARAPLADIB; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MYELOPEROXIDASE; PHOSPHOLIPID DERIVATIVE; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE;

ATHEROGENESIS; ATHEROSCLEROSIS; CELL INTERACTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; DIABETES MELLITUS; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYPERLIPIDEMIA; LIPID DEGRADATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ATHEROSCLEROSIS; HUMANS; LIPOPROTEINS; MICE;

EID: 67049143895     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32832bbd40     Document Type: Editorial

References (7)

1. Williams] KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15:551-561.
2. Devlin CM, Leventhal AR, Kuriakose G, et al. Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression. Arterioscler Thromb Vasc Biol 2008; 28:1723-1730. The first demonstration that deficiency of the secretory form of sphingomyelinase has a protective effect on atherosclerosis associated with reduction in lipoprotein retention.
3. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 2008; 451:904-913.
4. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-l Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290:2292-2300.
5. Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol 2006; 47:C7-C12.
6. Wilensky RL, Shi Y, Mohler ER 3rd, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary aiherosclerotio plaque development. Nat Med 2008; 14:1059-1066.
7. Serruys PW, Garcia-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008; 118:1172-1182. The first test of the effects of inhibition of Lp-PLA2 on parameters that are hypothesized to be related to the development of acute coronary event.